<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01491061</url>
  </required_header>
  <id_info>
    <org_study_id>653/2011/D</org_study_id>
    <nct_id>NCT01491061</nct_id>
  </id_info>
  <brief_title>Ranolazine Loading to Prevent PCI-induced Myocardial Injury</brief_title>
  <acronym>TWILIGHT</acronym>
  <official_title>TWice overnIght High-dose ranoLazIne Pretreatment for preventinG Myocardial iscHemic Damage in Patients With Stable Angina Undergoing percuTaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has previously been shown that pretreatment with ranolazine 1,000 mg twice daily for 7
      days can significantly reduce procedural myocardial injury in elective percutaneous coronary
      intervention (PCI). The investigators tested the hypothesis that twice overnight high-dose
      ranolazine loading before PCI can reduce the peri-procedural myocardial ischemic damage
      similarly to long-term pre-treatment with standard doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

      Ranolazine is a novel antianginal drug that reduces intracellular sodium and calcium
      accumulation during ischemia thus limiting ischemic injury.

      It has previously been shown that pretreatment with ranolazine 1,000 mg twice daily for 7
      days can significantly reduce procedural myocardial injury in elective percutaneous coronary
      intervention.

      It remains unknown, however, which of these two therapeutic approaches is more effective
      after PCI.

      Purpose

      The primary objective of this study is to test the hypothesis that twice overnight high-dose
      ranolazine loading before PCI can reduce the peri-procedural myocardial ischemic damage
      similarly to long-term pre-treatment with standard doses.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of PCI-induced myocardial infarction</measure>
    <time_frame>Up to 48 hours after PCI</time_frame>
    <description>Occurrence of peri-procedural myocardial infarction (i.e. creatine kinase-MB&gt;3 times the upper reference limit)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of post-PCI peak values of markers of myocardial damage</measure>
    <time_frame>Baseline and 48 hours after PCI</time_frame>
    <description>Changes after percutaneous coronary intervention in absolute values of creatine kinase, creatine kinase-MB, myoglobin, and troponin I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of 30-day MACE</measure>
    <time_frame>Up to 30 days after PCI</time_frame>
    <description>30-day incidence of major adverse cardiac events (MACE—death, myocardial infarction, target vessel revascularization)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of two preprocedural doses of Ranolazine 12 hours apart (1,000 mg the night before PCI and 1,000 mg prior to PCI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>os, 1,000 mg twice 12 hours apart prior to PCI</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa TM, Gilead, USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>os, two doses 12 hours apart prior to PCI</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Angiographically-proven coronary artery disease

          -  Class I indication to elective percutaneous coronary intervention

          -  Stable conditions

          -  No recent acute coronary syndromes

          -  Normal baseline values of markers of myocardial damage (creatine kinase, creatine
             kinase-MB, myoglobin, and troponin I)

          -  Able to understand and willing to sign the informed consent form

        Exclusion Criteria:

        • Women of child bearing potential patients must demonstrate a negative pregnancy test
        performed within 24 hours before
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francesco Pelliccia, MD</last_name>
    <phone>+393483392006</phone>
    <email>f.pelliccia@mclink.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>San Raffaele Pisana</name>
      <address>
        <city>Rome</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Marazzi, MD</last_name>
      <phone>+39 335 8381320</phone>
      <email>giuseppe.marazzi@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>December 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <last_update_submitted>March 6, 2013</last_update_submitted>
  <last_update_submitted_qc>March 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Francesco Pelliccia</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>periprocedural myocardial infarction</keyword>
  <keyword>ranolazine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

